News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly More inclisiran data ANGPTL3 monoclonal antibody evinacumab promising in homozygous familial hypercholesterolaemia FH in the MENA region: Gulf Registry launched Monogenic vs polygenic hypercholesterolaemia and cardiovascular risk ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »

Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide

ACC.20 with the World Congress of Cardiology

Virtual Meeting 28-30 March

Polygenic risk, LDL and SBP
Inclisiran: Data for >3,600 patients
Evinacumab: Nearly halves LDL-C in HoFH
ODYSSEY HoFH: Alirocumab shows benefit

AHA Scientific Sessions 2019

16-18 November, Philadelphia, USA

ORION-9: durable and potent LDL-C lowering in HeFH patients on twice yearly dosing
FOURIER: effects of evolocumab on cognition and following MI

Most viewed

More inclisiran data ODYSSEY HoFH: Alirocumab a potential adjunctive therapeutic option ANGPTL3 monoclonal antibody evinacumab promising in homozygous familial hypercholesterolaemia Polygenic risk scores, LDL and SBP in lifetime risk assessment VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a) New FOURIER analysis underlines consistent efficacy of evolocumab Dutch experience – Improving detection and care VIDEO: New insights from ODYSSEY OUTCOMES Implications from TESLA for FH management ODYSSEY APPRISE offers insights into the real world use of PCSK9 inhibitor

Most viewed

More inclisiran data

Hot Topics

News from the 11th Expert Meeting of the Editorial Board of PCSK9 Forum

LDL transcytosis in atherosclerosis: Professor Phil Shaul (Center for Pulmonary and Vascular Biology, University of Texas Southwestern Medical Center, Dallas, USA)

View the Webcast

Emerging lipid science – Apolipoprotein E and chronic disease: Professor Ruth Frikke-Schmidt (Rigshospitalet and Faculty of Health and Medical Sciences, University of Copenhagen, Denmark) discusses exciting research

View the Webcast

From the Editors

Monogenic versus polygenic familial hypercholesterolaemia: how does cardiovascular risk compare?

Does cardiovascular risk differ between individuals with monogenic hypercholesterolaemia or polygenic hypercholesterolaemia?
Prof. Derick Raal, University of the Witwatersrand, Johannesburg, South Africa, discusses a new report

Read the report

Other related reports:
Stratifying risk in familial hypercholesterolaemia: does coronary artery calcium have a role?
Read the report
A new genetic mechanism for familial hypercholesterolaemia: PCSK9 whole gene duplication
Read the report
Study reinforces the importance of cascade screening in families with familial hypercholesterolaemia
Read the report
Start treatment early: Maximise benefit
Read the report